Analytical Data
-
Gene name
AIPL1
- Application
-
Alternative Names
A930007I01Rik; Aipl1; AIPL1_HUMAN; AIPL2; Aryl hydrocarbon interacting protein like 1; Aryl hydrocarbon receptor interacting protein like 1; Aryl-hydrocarbon-interacting protein-like 1; LCA4; MGC25485; OTTHUMP00000128207; OTTMUSP00000006382; RP23-401C17.1
-
Species
Human
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NZN9
-
Expression Region
1-384aa
-
Molecular Weight
70.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
AIPL1 (Akinase Interacting Protein 1) is a crucial protein implicated in the pathogenesis of several retinal degenerative diseases, particularly Leber congenital amaurosis (LCA), a severe form of childhood blindness. Mutations in the AIPL1 gene disrupt normal retinal function and lead to photoreceptor cell death. Consequently, understanding the structure and function of AIPL1 is vital for developing targeted therapeutic strategies, including gene therapy and protein replacement approaches. Recent research has focused on the recombinant expression of AIPL1 to facilitate detailed biochemical and biophysical studies, with the aim of elucidating its interactions with other proteins and its role in phototransduction pathways. By producing and characterizing AIPL1 in various model systems, researchers aim to uncover the mechanisms underlying its function in retinal health and disease. This work not only enhances our understanding of AIPL1's biological significance but also paves the way for innovative treatments that could restore vision in patients suffering from AIPL1-related disorders. The successful reconstitution of AIPL1 as a recombinant protein serves as a foundational step towards these therapeutic developments, harnessing the potential of molecular biology to combat genetic causes of blindness.
